@entity270 for neuroleptic-induced XXXX .

@entity1 @entity270 @entity2358 @entity910 @entity161 @entity717
BACKGROUND: Antipsychotic (neuroleptic) medication is used extensively to treat @entity1 with chronic mental illnesses. Its use, however, is associated with adverse effects, including @entity717 such as @entity910 ( @entity910 ) - a problem often seen as repetitive @entity2358 around the mouth and face. @entity270 has been proposed as a treatment to prevent or decrease @entity910 . OBJECTIVES: To determine the effects of @entity270 for @entity1 with @entity161 or other chronic mental illnesses who also developed neuroleptic-induced @entity910 . SEARCH STRATEGY: We searched the Cochrane @entity161 Group Trials Register (March 2010), inspected references of all identified studies for further trials and contacted authors of trials for additional information. SELECTION CRITERIA: We included reports if they were controlled trials dealing with @entity1 with neuroleptic-induced @entity910 and @entity161 who had been randomly allocated to either @entity270 or to a placebo or no intervention. DATA COLLECTION AND ANALYSIS: We independently extracted data from these trials and we estimated risk ratios (RR) or mean differences (MD), with 95% confidence intervals (CI). We assumed that @entity1 who dropped out had no improvement. MAIN RESULTS: The review now includes 11 poorly reported randomised trials (total 427 @entity1 ). There was no clear difference between @entity270 and placebo for the outcome of 'clinically relevant improvement in @entity910 ' (6 trials, 256 @entity1 , RR 0.95 CI 0.89 to 1.02). For the outcome of 'any improvement in @entity910 symptoms', again, we found no clear difference between groups (7 trials, 311 @entity1 , RR 0.86 CI 0.75 to 1.00). However, @entity1 allocated to placebo showed more deterioration of their symptoms compared with those given @entity270 (5 trials, 98 @entity1 , RR 0.38 CI 0.16 to 0.9). There was no difference in the incidence of adverse effects (9 trials, 203 @entity1 , RR 1.29 CI 0.51 to 3.24) or leaving the study early (medium term 6 trials, 173 @entity1 , RR 1.29 CI 0.72 to 2.3). There is no trial-based information regarding the effect of @entity270 for those with early onset of @entity910 . AUTHORS' CONCLUSIONS: Small trials of limited quality suggest that @entity270 may protect against @entity910 . There is no evidence that @entity270 improves symptoms of this problematic and disfiguring condition once established. New and better trials are indicated in this under-researched area, and, of the many adjunctive treatments that have been given for @entity910 , @entity270 would be a good choice for further evaluation.
